Neuroscience drug discovery is complex and time-consuming. The vast majority of drug candidates fail before reaching clinical trials and for most neurodegenerative diseases there are no disease-modifying therapies.
One of the reasons for slow progress in neuroscience drug discovery is the lack of suitable models, particularly cell models. Primary animal cells, such as isolated neurons or microglia, are often used in mono-culture for phenotypic screening and lead optimisation assays but these mono-cultures fail to recapitulate the complexity of the brain or communication between different cell types within in.
In this webinar our neuroscience experts will discuss the advantages of using human induced pluripotent stem cell (iPSC)-derived cells, such as neurons, microglia, and oligodendrocytes, in drug discovery assays. We will outline how these cells can be used in complex cell cultures, combining cell types found in the brain to provide better models for neuroscience drug discovery.
Register today to learn more about multi-cell models of myelination and neuroinflammation, and how these models can be used with various assays and endpoints to support neuroscience research.
Key Learning Objectives
- Hear how human iPSCs can be a source of cells for screening assays and in vitro pharmacology
- Learn more about the advantages of multi-cell cultures over mono-cultures
- Understand how our experts have built models for myelination and neuroinflammation
- Learn how these models can be used in neuroscience drug discovery
Register